Mechano-energetic Uncoupling in Hypertrophic Cardiomyopathy: Pathophysiological Mechanisms and Therapeutic Opportunities

Overview

Journal J Mol Cell Cardiol Plus

Date 2025 Jan 13

PMID 39801694

Authors

Vasco Sequeira

Mark T Waddingham

Hirotsugu Tsuchimochi

Christoph Maack

James T Pearson

Affiliations

Soon will be listed here.

Abstract

Hypertrophic cardiomyopathy (HCM) is a frequent inherited form of heart failure. The underlying cause of HCM is generally attributed to mutations in genes that encode for sarcomeric proteins, but the pathogenesis of the disease is also influenced by non-genetic factors, which can contribute to diastolic dysfunction and hypertrophic remodeling. Central to the pathogenesis of HCM is hypercontractility, a state that is an antecedent to several key derangements, including increased mitochondrial workload and oxidative stress. As a result, energy depletion and mechano-energetic uncoupling drive cardiac growth through signaling pathways such as ERK and/or potentially AMPK downregulation. Metabolic remodeling also occurs in HCM, characterized by decreased fatty acid oxidation and increased glucose uptake. In some instances, ketones may also feed the heart with energy and act as signaling molecules to reduce oxidative stress and hypertrophic signaling. In addition, arrhythmias are frequently triggered in HCM, resulting from the high Ca-buffering of the myofilaments and changes in the ATP/ADP ratio. Understanding the mechanisms driving the progression of HCM is critical to the development of effective therapeutic strategies. This paper presents evidence from both experimental and clinical studies that support the role of hypercontractility and cellular energy alterations in the progression of HCM towards heart failure and sudden cardiac death.

References

Bertero E, Nickel A, Kohlhaas M, Hohl M, Sequeira V, Brune C . Loss of Mitochondrial Ca Uniporter Limits Inotropic Reserve and Provides Trigger and Substrate for Arrhythmias in Barth Syndrome Cardiomyopathy. Circulation. 2021; 144(21):1694-1713. DOI: 10.1161/CIRCULATIONAHA.121.053755. View

Hegyi B, Polonen R, Hellgren K, Ko C, Ginsburg K, Bossuyt J . Cardiomyocyte Na and Ca mishandling drives vicious cycle involving CaMKII, ROS, and ryanodine receptors. Basic Res Cardiol. 2021; 116(1):58. PMC: 8516771. DOI: 10.1007/s00395-021-00900-9. View

Steendijk P, Meliga E, Valgimigli M, Ten Cate F, Serruys P . Acute effects of alcohol septal ablation on systolic and diastolic left ventricular function in patients with hypertrophic obstructive cardiomyopathy. Heart. 2008; 94(10):1318-22. DOI: 10.1136/hrt.2007.139535. View

Betocchi S, Hess O, Losi M, Nonogi H, KRAYENBUEHL H . Regional left ventricular mechanics in hypertrophic cardiomyopathy. Circulation. 1993; 88(5 Pt 1):2206-14. DOI: 10.1161/01.cir.88.5.2206. View

Thompson W, Hornby B, Manuel R, Bradley E, Laux J, Carr J . A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. 2020; 23(3):471-478. PMC: 7935714. DOI: 10.1038/s41436-020-01006-8. View

Allen D, Orchard C . Myocardial contractile function during ischemia and hypoxia. Circ Res. 1987; 60(2):153-68. DOI: 10.1161/01.res.60.2.153. View

Wijnker P, Sequeira V, Foster D, Li Y, Dos Remedios C, Murphy A . Length-dependent activation is modulated by cardiac troponin I bisphosphorylation at Ser23 and Ser24 but not by Thr143 phosphorylation. Am J Physiol Heart Circ Physiol. 2014; 306(8):H1171-81. PMC: 3989756. DOI: 10.1152/ajpheart.00580.2013. View

Niemeyer C . RAS diseases in children. Haematologica. 2014; 99(11):1653-62. PMC: 4222471. DOI: 10.3324/haematol.2014.114595. View

Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici P . Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 2003; 349(11):1027-35. DOI: 10.1056/NEJMoa025050. View

10.

Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C . Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003; 107(17):2227-32. DOI: 10.1161/01.CIR.0000066323.15244.54. View

11.

Bedi Jr K, Snyder N, Brandimarto J, Aziz M, Mesaros C, Worth A . Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure. Circulation. 2016; 133(8):706-16. PMC: 4779339. DOI: 10.1161/CIRCULATIONAHA.115.017545. View

12.

Wijnker P, Friedrich F, Dutsch A, Reischmann S, Eder A, Mannhardt I . Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue. J Mol Cell Cardiol. 2016; 97:82-92. DOI: 10.1016/j.yjmcc.2016.03.003. View

13.

Mustroph J, Wagemann O, Lucht C, Trum M, Hammer K, Sag C . Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes. ESC Heart Fail. 2018; 5(4):642-648. PMC: 6073019. DOI: 10.1002/ehf2.12336. View

14.

Nakamura K, Kusano K, Matsubara H, Nakamura Y, Miura A, Nishii N . Relationship between oxidative stress and systolic dysfunction in patients with hypertrophic cardiomyopathy. J Card Fail. 2005; 11(2):117-23. DOI: 10.1016/j.cardfail.2004.05.005. View

15.

Sequeira V, Najafi A, McConnell M, Fowler E, Bollen I, Wust R . Synergistic role of ADP and Ca(2+) in diastolic myocardial stiffness. J Physiol. 2015; 593(17):3899-916. PMC: 4575576. DOI: 10.1113/JP270354. View

16.

Bertero E, Maack C . Metabolic remodelling in heart failure. Nat Rev Cardiol. 2018; 15(8):457-470. DOI: 10.1038/s41569-018-0044-6. View

17.

Davis J, Davis L, Correll R, Makarewich C, Schwanekamp J, Moussavi-Harami F . A Tension-Based Model Distinguishes Hypertrophic versus Dilated Cardiomyopathy. Cell. 2016; 165(5):1147-1159. PMC: 4874838. DOI: 10.1016/j.cell.2016.04.002. View

18.

Fraysse B, Weinberger F, Bardswell S, Cuello F, Vignier N, Geertz B . Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. J Mol Cell Cardiol. 2012; 52(6):1299-307. PMC: 3370652. DOI: 10.1016/j.yjmcc.2012.03.009. View

19.

Nollet E, Duursma I, Rozenbaum A, Eggelbusch M, Wust R, Schoonvelde S . Mitochondrial dysfunction in human hypertrophic cardiomyopathy is linked to cardiomyocyte architecture disruption and corrected by improving NADH-driven mitochondrial respiration. Eur Heart J. 2023; 44(13):1170-1185. PMC: 10067466. DOI: 10.1093/eurheartj/ehad028. View

20.

Chowdhury S, Jackson L, Byrne B, Bryant R, Cade W, Churchill T . Longitudinal Observational Study of Cardiac Outcome Risk Factor Prediction in Children, Adolescents, and Adults with Barth Syndrome. Pediatr Cardiol. 2022; 43(6):1251-1263. PMC: 9462389. DOI: 10.1007/s00246-022-02846-8. View